Please login to the form below

Not currently logged in
Email:
Password:

Micreos appoints chief medical officer

Dr Johan Frieling brings experience from Bayer and Genzyme

Micreos Dr Johan FrielingDutch biotech company Micreos has appointed Dr Johan Frieling as its new chief scientific officer.

In his new role Dr Frieling will be responsible for overseeing Micreos' antibiotic alternative, Staphefekt, as it begins clinical trials.

Mark Offerhaus, founder and chief executive officer of Micreos, said: “Johan has successfully developed a number of biopharmaceutical products up to FDA and EMA approval.

“For us he is the ideal person to lead Staphefekt to market in the new indications.”

Dr Frieling has over 20 years of clinical development experience and has previously held senior positions at Bayer, Genzyme and Pharmasquire Consultancy.

He joins Micreos from LFB Biotechnologies where he served most recently as director of global clinical research, with responsibility for all development products at the company.

Dr Freiling said: “It's a great time to be joining Micreos … I look forward to sharing my knowledge and leading the clinical development of Staphefekt, ultimately helping a large cohort of patients across the globe.”

23rd March 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics